Global Perspectives in Lung Cancer – WCLC 2023
Expert perspectives and strategic insights on the latest therapeutic developments and translational research coming out of WCLC 2023 regarding lung cancer treatment.
September 25 and 29, 2023
FACULTY CHAIR
Corey Langer, MD, FACP
University of Pennsylvania, Philadelphia, PA, US
Faculty Members
Natasha B. Leighl, MD, FRCPC, FASCO
University of Toronto, ON, Canada
Nasser Hanna, MD
Indiana University School of Medicine, Indianapolis, IN, US
Ignacio I. Wistuba, MD
MD Anderson Cancer Center, Houston, TX, US
Mark A. Socinski, MD
AdventHealth Cancer Institute, Orlando, FL, US
Enriqueta Felip, MD, PhD
Vall d’Hebron University Hospital, Barcelona, Spain
Solange Peters, MD, PhD
University Hospital of Lausanne, Switzerland
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer: The Pathologist’s Perspective
- New Directions for EGFR-Mutant NSCLC
- EGFR (Less Common Mutations, Including Exon 20 Insertions)
- Therapeutic Landscape for Fusion-Positive NSCLC (ALK, ROS1, NTRK, RET)
- Inhibiting Oncogenic Mutations: Overcoming Mutant KRAS, HER2, MET, and BRAF
- Promising New Targets/Agents in Lung Cancer: ADCs and Beyond
- Immunotherapy in Early NSCLC
- Immunotherapy in Unresectable Stage III NSCLC
- First-Line Immunotherapy in Metastatic NSCLC: Single Agent or Combination?
- New Directions for Second-Line Therapy
- Emergence of Immunotherapy and New Agents in SCLC
